Mutti D O, Zadnik K, Egashira S, Kish L, Twelker J D, Adams A J
School of Optometry, University of California, Berkeley 94720.
Invest Ophthalmol Vis Sci. 1994 Feb;35(2):515-27.
The purpose of this study was to examine the effect of cycloplegic agent on the measurement of refractive error and the ocular components.
We compared two commonly used topical cycloplegic agents, 1% tropicamide and 1% cyclopentolate, for their effect on the measurement of refractive error (by Canon R-1 autorefraction), accommodative response (by Canon R-1 autorefraction and by the conventional, subjective "pushup" method), crystalline lens power (by video phakometry and by calculation), and axial ocular dimensions (by A-scan ultrasonography) in 20 emmetropic to moderately hyperopic children.
Comparison of refractive error at each drug's reported time of maximum cycloplegia (30 minutes for tropicamide and 60 minutes for cyclopentolate) showed that distance autorefraction in the vertical meridian differed by +0.20 +/- 0.30 diopters (D) (P = 0.008). The average difference was +0.07 +/- 0.10 mm for anterior chamber depth (P = 0.004), -0.03 +/- 0.05 mm for crystalline lens thickness (P = 0.025), -0.65 +/- 0.69 D for phakometrically measured crystalline lens power (P < 0.001), +0.03 +/- 1.55 D for calculated crystalline lens power (P = 0.94), and -0.09 +/- 0.19 mm for vitreous chamber depth (P = 0.062, all paired t tests; positive signs denote greater values with cyclopentolate). Residual accommodation was 0.47 and 0.67 D greater with tropicamide when measured by autorefraction and the pushup method (P = 0.013 and 0.08 respectively, paired t test). All significant differences were consistently in the direction of poorer cycloplegia with tropicamide.
Although tropicamide, as expected, showed poorer cycloplegia compared to cyclopentolate, the degree of difference appeared to be small, with minimal effect on the measurement of distance refractive error and the ocular optical components.
本研究旨在探讨睫状肌麻痹剂对屈光不正测量及眼内结构的影响。
我们比较了两种常用的局部睫状肌麻痹剂,1%托吡卡胺和1%环喷托酯,观察它们对20名正视至中度远视儿童的屈光不正测量(使用佳能R-1自动验光仪)、调节反应(使用佳能R-1自动验光仪和传统主观“上推”法)、晶状体屈光度(通过视频晶状体测量法和计算)以及眼轴长度(通过A超超声检查)的影响。
在每种药物报告的最大睫状肌麻痹时间(托吡卡胺为30分钟,环喷托酯为60分钟)时比较屈光不正,结果显示垂直子午线方向的远距离自动验光结果相差+0.20±0.30屈光度(D)(P = 0.008)。前房深度平均相差+0.07±0.10毫米(P = .004),晶状体厚度相差-0.03±0.05毫米(P = 0.025),晶状体测量屈光度相差-0.65±0.69 D(P < 0.001),计算的晶状体屈光度相差+0.03±1.55 D(P = 0.94),玻璃体腔深度相差-0.09±0.19毫米(P = 0.062,均为配对t检验;正值表示环喷托酯测量值更大)。通过自动验光和上推法测量时,托吡卡胺的残余调节分别比环喷托酯大0.47 D和0.67 D(配对t检验,P分别为0.013和0.08)。所有显著差异均一致表明托吡卡胺的睫状肌麻痹效果较差。
尽管如预期的那样,托吡卡胺的睫状肌麻痹效果比环喷托酯差,但差异程度似乎较小,对远距离屈光不正测量和眼内光学结构的影响最小。